System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Giampiero Girolomoni is an expert in Dermatology at Azienda Ospedaliera Universitaria Integrata Verona (Italy). As of October 2026, ScienceLeadR ranks Giampiero Girolomoni in the top 1% of experts worldwide for Psoriasis, Dermatitis and Skin Diseases, Papulosquamous. Giampiero Girolomoni has authored 810 publications, the most recent in 2026, and is an investigator in 6 clinical trials, 1 of them ongoing. SLR score: 2,516 (community average: 125). How the SLR is computed.

LeadR Profile

Giampiero Girolomoni Azienda Ospedaliera Universitaria Integrata Verona Italy
2 516 ScienceLeadR Reputation 2516

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Public Health - Immunology - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1989 - 2026
Source: PubMed

University of Verona

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 810

Citations

Citations: 35 555 1st author: 53 Last author: 357 Unique author: 3

Main journals

J Eur Acad Dermatol Venereol 85
Br J Dermatol 50
J Am Acad Dermatol 33
J Invest Dermatol 29
G Ital Dermatol Venereol 28

Best Journals

Nat Med 2
JAMA 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Real-life effectiveness and safety of lebrikizumab in older patients with atopic dermatitis: a multicentre study.
PMID 42423183 — safety, dermatitis, aged, dermatology, dermatitis, atopic		Clin Exp Dermatol20260
Long-Term Changes in Complete Blood Count-Derived Inflammatory Indices During Risankizumab Treatment for Psoriasis: A 208-Week Multicenter Real-World Study.
PMID 42930039 — blood, lymphocytes, biomarkers, antibodies, monoclonal, therapeutics, psoriasis		Antibodies (Basel)20260
Clinical Characteristics of Patients Presenting with Moderate-to-Severe Atopic Dermatitis and Concomitant Inflammatory Bowel Diseases: a Multicenter Retrospective Study.
PMID 42858396 — dermatitis, retrospective studies, inflammatory bowel diseases, prevalence, diagnosis, dermatitis, atopic		Dermatol Pract Concept20260
Efficacy and Safety of Delgocitinib and Its Impact on Patient's Perspective for Moderate-to-severe Chronic Hand Eczema in Adults: A 16-week Real-world Prospective Multicentre Study.
PMID 42839349 — safety, eczema		Acta Derm Venereol20260
New-Onset Pemphigus Following Drug Exposure and Vaccination: A Systematic Review of Reported Cases.
PMID 42797648 — vaccines, pharmaceutical preparations, causality, vaccination, therapeutics, pharmacovigilance, pemphigus		Vaccines (Basel)20260

Clinical Studies 6

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

N/A 2
Phase 4 2
Phase 2 1
Phase 3 1

By status:

Completed 4
Recruiting 1
Unknown 1

By type:

Interventional 5
Observational 1

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 0
multicentricup10 3

Main Topics

Cohort/Consortium Investigators 4

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Post Marketing Clinical Follow Up Trial to Evaluate the Performance and Safety of the Medical Device 047 TD Dermatitis Cream in Adults and Children With Atopic and Contact Dermatitis Symptoms Confirmed by Clinical Parameters
NCT07056569 — skin, marketing, safety, dermatitis, eczema, signs and symptoms, child, dermatitis, atopic, dermatitis, contact, medical devices		N/ARecruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS